<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03046511</url>
  </required_header>
  <id_info>
    <org_study_id>CMC-16-0067-CTIL</org_study_id>
    <nct_id>NCT03046511</nct_id>
  </id_info>
  <brief_title>Peritonitis Prevention After Insertion of Peritoneal Dialysis Catheter.</brief_title>
  <official_title>Peritonitis Prevention After Insertion of Peritoneal Dialysis Catheter. Comparison Between Post - Surgical Intraperitoneal Vs. Intravenous Pre- Surgical Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carmel Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An intraperitoneal implanted catheter is always necessary to perform Peritoneal Dialysis.
      Catheter insertion has been associated with infectious complication such as Exit Site
      Infection (ESI), Tunnel Infection and Peritonitis. The last one may lead to loss of the
      technique because the need of catheter removal. Most of international guidelines recommends
      the use of prophylactic antibiotics. Different protocols has been used, mostly intravenous
      single injection before the procedure. For the last 25 years our unit gives a single
      intraperitoneal dose of Cefazolin immediately after the catheter insertion. The aim of this
      study is compare the effect of a pre- operative IV dose os Cefazolin with a post- procedure
      intraperitoneal single dose administration of the same drug.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peritonitis</measure>
    <time_frame>14 days</time_frame>
    <description>Peritonitis asscociated catheter defined by cloudy effluent, high leukocyte count with neutrofilia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exit site infection</measure>
    <time_frame>14 days</time_frame>
    <description>Infection defined by purulent discharge or local redness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tunnel infection</measure>
    <time_frame>14 days</time_frame>
    <description>Inflammation in the subcutaneous tract of the peritoneal catheter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Peritoneal Dialysis-associated Peritonitis</condition>
  <condition>Peritoneal Dialysis Catheter Infection</condition>
  <condition>Peritoneal Dialysis Complication</condition>
  <arm_group>
    <arm_group_label>Intraperitoneal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One single dose of intraperitoneal Cefazolin 1000 mg via the recently inserted peritoneal catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One single dose of intravenous Cefazolin 1000 mg one hour before catheter insertion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>A post- procedure administration of Cefazolin will be compared with a pre-operative intravenous dose</description>
    <arm_group_label>Intraperitoneal</arm_group_label>
    <arm_group_label>Intravenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects suffering from Chronic Kidney Disease, candidates to a intra- peritoneal catheter
        insertion

        Exclusion Criteria:

        Pregnancy; Active antibiotic treatment before the procedure; Known allergy to Cefazolin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Victor Frajewicki, MD</last_name>
    <phone>972-4-8250491</phone>
    <email>vfraje@clalit.org.il</email>
  </overall_contact>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2017</study_first_submitted>
  <study_first_submitted_qc>February 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>February 5, 2017</last_update_submitted>
  <last_update_submitted_qc>February 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carmel Medical Center</investigator_affiliation>
    <investigator_full_name>Victor Frajewicki, MD</investigator_full_name>
    <investigator_title>Head, Department of Nephrology and Hypertension</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

